BREVAGenplus(R) Offers a Solution to Physicians Concerned About the Revised Breast Cancer Screening Guidelines from the American Cancer Society (ACS)

Phenogen Sciences, Inc., the U.S. subsidiary of Australia-based Genetic Technologies Limited

and maker of BREVAGenplus, today commented on the American Cancer Society's (ACS) recent changes to its breast cancer screening guidelines. These guidelines, which are aimed at women with an average risk of breast cancer, raised the recommended age for first mammogram to 45 and suggested women over age 55 switch to biennial mammograms. However, the recommendations also create clinical ambiguity by concluding that women between ages 40 and 44 should still have the choice to get annual mammograms, and that women 55 years and older should likewise have the opportunity to continue annual screenings.1 BREVAGenplus, a clinically-validated, genetically-based breast cancer risk assessment test, can help physicians resolve this ambiguity by identifying which women without a family history still warrant earlier and/or more frequent screening. "The ACS' changes to its breast cancer screening guidelines, presents a challenge for physicians to identify who is appropriate for mammography screening before the age of 45 and annually after age 55. BREVAGenplus offers a solution, by providing physicians with a more accurate assessment of a patient's risk of developing sporadic breast cancer. This assessment can